LCM
YMAB

Laurion Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Laurion Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,000
Closed -$305K – 1359
2018
Q4 		$305K Hold
15,000
– – 0.01% 828
2018
Q3 		$398K Buy
+15,000
New +$381K ﹤0.01% 884

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Laurion Capital Management's YMAB Position: Q1 2019 in Review

Laurion Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2019, closing a stake of 15,000 shares — an estimated $305K sold.

Laurion Capital Management first reported a position in YMAB in Q3 2018 and held it in 2 quarters. The position peaked at $398K in Q3 2018. 45 funds tracked by Wall St. Rank hold YMAB as of Q1 2019.

  • Laurion Capital Management reported no remaining Y-mAbs Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Laurion Capital Management sold 15,000 Y-mAbs Therapeutics shares in Q1 2019, an estimated $305K.
  • Laurion Capital Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 2 quarters.
  • Laurion Capital Management's Y-mAbs Therapeutics position peaked at $398K in Q3 2018.
  • 45 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2019.

Based on Laurion Capital Management's 13F filing for Q1 2019, filed 8 May 2019.